C4 Therapeutics, Inc.
CCCCHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, C4 Therapeutics, Inc. (CCCC) is listed under Biotechnology. The company carries a $376.5M market cap, placing it firmly in the small-cap category. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
Market Cap
$376.5M
Beta
3.08
P/E (TTM)
—
P/E (Fwd)
-3.18
EPS (TTM)
$-0.91
EPS (Fwd)
$-0.96
ROE
-48.1%
ROA
-19.3%
Cash
$253.7M
Total Debt
$56.9M
Free CF
-$43.7M
52W Change
15.5%
Annual Financials
Cash vs Debt
Where CCCC stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CCCC finished 16.23% below its 150-day moving average ($3.45) and 8.54% below its 200-day moving average ($3.16). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CCCC overbought or oversold?
At the October 20, 2026 close, CCCC's RSI(14) was 44.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
C4 Therapeutics, Inc. holds $253.7M in cash against $56.9M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$43.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -48.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $31.1M to $35.9M.
C4 Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, CCCC has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence C4 Therapeutics, Inc.'s trajectory.